AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00267202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.
Study NCT05728710 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Description: standard ESD performed and complicated with a perprocedural or delayed perforation
Study NCT01766466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
Study NCT01766466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.
Study NCT00830310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation module
Description: Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item).
Study NCT00830310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance use module
Description: Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
Study NCT00830310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved communication/rapport with provider module
Description: Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module.
Study NCT00830310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication routines management module
Description: Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI.
Study NCT02254876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program
Description: Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
Study NCT02254876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy program
Description: Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
Study NCT02254876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroMuscular Taping (NMT)
Description: The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus.
Study NCT04029246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow up phone call
Description: Telephone call to ask if patient has received letter and whether they would like an appointment
Study NCT04029246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Offer of a shopping voucher if patient attends for appointment
Study NCT00370994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural injection
Description: Caudal epidural injection with catheterization
Study NCT00370994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous adhesiolysis
Description: Percutaneous adhesiolysis with hypertonic saline neurolysis
Study NCT02298790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal schedule
Study NCT00514059 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Boostrix polio
Description: 1 dose (0.5 ml) i.m.
Study NCT02699918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nocturnal oximetry
Description: nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
Study NCT01288716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Study NCT02086110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Study NCT02086110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Study NCT03576248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-phase 6 Hz prefronto-parietal tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
Study NCT03576248 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham prefronto-parietal tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
Study NCT03576248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA left prefrontal tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study NCT03576248 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham left prefrontal tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study NCT02983071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Study NCT02983071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT05087654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of 3D VR and Hands-on Horticultural Activities
Description: The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
Study NCT01351116 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EBR
Description: EBR of 20 Gy in 5 daily fractions over one week
Study NCT01627938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DRZ) plus Mitoxantrone (MX)
Description: Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
Study NCT01627938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Mitoxantrone (MX)
Description: MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
Study NCT01649258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron transdermal system
Description: Given granisetron transdermal system patch
Study NCT01649258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: Given IV
Study NCT01649258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00096512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00096512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02619695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fastjel
Description: 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
Study NCT02619695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fastjel
Description: 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
Study NCT01869192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 90 mg/m2 d1 q3w
Study NCT01869192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 d1 q3w
Study NCT01869192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 d1 q3w
Study NCT01869192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2/dose bid x 14d q3w
Study NCT01869192 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Standard dosing, fields depending on clinical findings
Study NCT00640705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Study NCT00640705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo patch
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Study NCT04134000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
Study NCT04134000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
Study NCT01015352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
Study NCT01015352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: Epoetin beta : 60000U weekly SQ injections~NeoRecormon®
Study NCT04601051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTLA-2001
Description: A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
Study NCT03898661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase histiolyticum
Description: local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
Study NCT03951246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and Motor Training
Description: In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo .....~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again.
Study NCT01067768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily review
Description: Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter
Study NCT02027844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Cartoon watching by children during inhalational induction of sevoflurane
Study NCT02027844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental presence
Description: parental presence during inhalational induction of sevoflurane
Study NCT02027844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental presence
Description: parental presence during inhalational induction of sevoflurane
Study NCT02181556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease
Study NCT02181556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease
Study NCT04499118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT regimen
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
Study NCT04499118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen
Description: Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
Study NCT01965808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study NCT01687491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENOXA®
Description: enoxaparine 100 UI/Kg subcutaneous injection
Study NCT01687491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOVENOX®
Description: enoxaparine 100 UI/Kg subcutaneous injection
Study NCT02908113 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: collection data
Study NCT02487524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold water test
Description: The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
Study NCT02487524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autonomic nervous system monitoring
Description: The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
Study NCT02487524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QST
Description: Quantitative sensory testing.
Study NCT02908113 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IRM
Study NCT02286193 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient clinical encounters with Community Resource Specialist (CRS)
Description: CRS will work with patients to create goals, develop action plans and link to community resources to support goals
Study NCT00807534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: ipratropium bromide nebulization
Study NCT00807534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo nebulization
Study NCT00807534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: constant rate step test
Description: nebulization of 500ug
Study NCT00807534 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: constant rate step test
Description: nebulization of 500ug
Study NCT00807534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: constant rate shuttle walk test
Description: nebulization of 500ug
Study NCT00807534 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: constant rate shuttle walk test
Description: nebulization of 500ug
Study NCT00555984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol + Remifentanil
Description: Administered intravenously during surgery for maintenance of General Anesthesia
Study NCT00555984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane + Remifentanil
Description: the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
Study NCT01767376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
Study NCT03165227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Taken orally
Study NCT03165227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken orally
Study NCT02911311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of conbercept
Description: conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
Study NCT02911311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
Study NCT01957202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/levocabastine
Description: FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study NCT01957202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study NCT01957202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocabastine
Description: levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study NCT01710709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 400mg or 300mg, intramuscular injections every 4 weeks.
Study NCT01659411 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Yearly clinical visits
Study NCT03698032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Participants will consume water only
Study NCT03698032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 oz Pistachios
Description: Participants will consume water plus 1.5 oz of pistachios as the intervention
Study NCT03698032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3.0 oz Pistachios
Description: Participants will consume water plus 3.0 oz of pistachios as the intervention